This evidence suggests a promising approach for immunotherapy in PAAD, LGG, and STAD patients, underscoring the potential for these signatures to inform innovative therapeutic strategies involving anti-AXL antibodies and small molecule AXL kinase inhibitors. The gene discussed is AXL; the disease is pancreatic adenocarcinoma.